Emergence of IGH::CCND1 Rearrangement and Mutations in TP53, BTK, and BCL2 Associated With Therapy Resistance in Chronic Lymphocytic Leukemia

Authors

Qing Wei
Hong Fang
James M Jing
Roman Segura-Rivera
L Jeffrey Medeiros
Wei Wang

Publication Date

12-1-2024

Journal

EJHaem

DOI

10.1002/jha2.1024

PMID

39691246

PMCID

PMC11647697

PubMedCentral® Posted Date

10-8-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Chronic lymphocytic leukemia (CLL) is an indolent low-grade B-cell neoplasm that generally responds well to treatment. Rarely, CLL cases exhibit an IGH::CCND1 rearrangement, presenting a diagnostic challenge in distinguishing between clonal evolution within CLL and an independent mantle cell lymphoma. We report a case of CLL with the emergence of an IGH::CCND1 rearrangement and mutations associated with treatment resistance, including TP53, BTK, and BCL2, during disease progression. Immunophenotypic, cytogenetic, and molecular analyses support that these alterations are secondary events within the CLL clone. This case demonstrates dynamic clonal selection and expansion in response to treatments, which, in turn, contributes to treatment resistance.

Keywords

CLL, IGH:CCND1 rearrangement, mutations, therapy‐resistance

Published Open-Access

yes

Recommended Citation

Wei, Qing; Fang, Hong; Jing, James M; et al., "Emergence of IGH::CCND1 Rearrangement and Mutations in TP53, BTK, and BCL2 Associated With Therapy Resistance in Chronic Lymphocytic Leukemia" (2024). Faculty, Staff and Student Publications. 5102.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5102